source
- AI drug developer Pathos secures $237 million Series E, valuation hits $3 billionPathos announced a $237 million Series E round led by Bristol Myers Squibb, lifting its valuation to about $3 billion. The funding will support expansion beyond oncology into neurology, leveraging…
- Few European-approved cancer drugs deliver high clinical benefit, analysis showsA new analysis of European regulator approvals between Jan 2022 and July 2026 finds that most newly approved cancer medicines provide limited clinical benefit. Out of 97 approved indications acros…